Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this report, a 2-year-old male with GAPO syndrome exhibited androgenetic-like alopecia with normal testosterone levels and telogen hair loss, which are novel findings for this condition.

This source reports that telogenic hair loss, while not leading to complete baldness, significantly impacts patients' quality of life due to its effects on their psychoemotional state; no standardized treatment currently exists, so therapy focuses on addressing trigger factors and psychological well-being.

In this study, 20 patients with telogen alopecia showed reduced hair loss and improved hair quality after 9 weeks of treatment with the topical product "Time to Grow" and the dietary supplement "Thick and Strong Hair.

This study found that combining iron supplements with physiotherapy resulted in improved hair growth and condition in women with telogen alopecia and mild iron deficiency anemia.

This study found that combining iron supplements with physiotherapy improved hair condition and growth in women with iron deficiency-related telogen hair loss compared to iron supplements alone.

This review discusses the increased incidence of hair loss and telogen effluvium among COVID-19 patients and evaluates existing evidence for regenerative treatments like PRP and HFSCs, finding limited published data.

This case study reports a pattern of psychogenic telogen effluvium with temporary hair loss following a C5 complete spinal cord injury, recovering fully except for minor hair loss at the occiput.

This study found that oral vitamin D3 therapy significantly improved hair regrowth in women with telogen effluvium in southern Punjab, Pakistan, especially among younger women not using sunscreen but consuming milk or milk protein.

This review discusses "follicular hypoglycania" as a potential pathology in hair growth disorders and reports that proteoglycan replacement therapy may improve hair loss treatments, though it presents no new clinical trial results.

The researchers reported that COVID-induced telogen effluvium can occur after both severe and mild infections, potentially presenting earlier than other causes, and necessitates specific patient management due to its psychological impact.

In this study, researchers observed an increased incidence of pattern hair loss and telogen effluvium among COVID-19 patients, potentially linked to psychological stress, systemic inflammation, and oxidative stress, with reduced anagenic expression of proteoglycans suggested as a mediating mechanism.

This review discusses the link between COVID-19 and diffuse hair loss, focusing on the potential of proteoglycan replacement therapy with Nourkrin® to treat pattern hair loss and telogen effluvium in affected patients, and reports no new clinical results.

In this study, detailed examinations of alopecic lesions in two female Cronkhite-Canada syndrome patients suggested hair regrowth might occur without systemic corticosteroids if not required for gastrointestinal treatment, and hair loss may begin with anagen-telogen transition.

This letter to the editor discusses the immune response related to hair loss in a case of atypical drug-induced hypersensitivity syndrome but reports no new research findings.

This review discusses the mechanisms, causes, and treatment options for telogen effluvium, noting acute cases often resolve by addressing causative factors, while chronic forms remain challenging to treat; recent causes include post-hair transplantation, vitamin D deficiency, and COVID-19.

In this study, postpartum telogen effluvium was often accompanied by other hair loss disorders, highlighting the importance of recognizing these conditions for proper diagnosis and treatment.

This study suggests that stress negatively affects hair growth by inducing inflammation and early hair cycle transitions in mice, which might inform strategies for managing stress-related hair loss in humans.

This review discusses the shedding phase of the hair cycle, known as exogen, and reports no new findings while analyzing related processes like club fiber formation and release.

This study found that chronic telogen effluvium is a distinct condition from female pattern hair loss, with different pathogenic mechanisms observed in histomorphometric analyses.

This study observed that women with telogen effluvium had significantly lower vitamin D levels compared to control subjects, suggesting a possible link between vitamin D deficiency and this type of hair loss.

This review identifies a significant link between telogen effluvium and increased psychological distress, including anxiety, depression, and social phobia, stressing the need for both medical and psychological care to improve affected individuals' quality of life.

This study found that telogen effluvium, a type of hair loss, was prevalent among 24% of COVID-19 patients, likely triggered by stress and medication related to the illness.

This study found that trichoscopy can effectively differentiate female pattern hair loss from chronic telogen effluvium based on specific features like hair shaft diameter variability and density differences, aiding in targeted treatment planning.

This study found that anxiety-related traits significantly predict the impact of hair loss on quality of life across different alopecia types, with variations observed based on gender.

This study found that inadequate ferritin levels, rather than haemoglobin levels, indicated iron deficiency in women with telogen effluvium, alopecia areata, and female pattern hair loss.

In this study, researchers reported that intradermal injections of Dr. SKS hair booster serum improved hair growth and patient satisfaction in individuals experiencing COVID-19-induced persistent telogen effluvium, with increased benefits observed over six months.

This systematic review found an increased incidence of hair loss and telogen effluvium among COVID-19 patients and reported preliminary effectiveness of platelet-rich plasma, adipose-derived mesenchymal stem cells, and human follicle stem cells for treatment without major side effects.

The researchers reported that an oral supplement containing hydrolysed fish-origin collagen, taurine, cysteine, methionine, iron, and selenium significantly improved the effectiveness of anti-hair loss treatments in people with androgenic alopecia or chronic telogen effluvium after 12 weeks, compared to drug treatments alone.

The authors describe a case where a 24-year-old woman experienced diffuse hair loss, likely telogen effluvium, after bariatric surgery, suggesting nutritional deficiencies and multifactorial causes may contribute to this condition.

This article is a case report on severe hair loss due to telogen effluvium occurring during inpatient rehabilitation and does not provide new clinical results.